FDA has issued a final guidance to increase diversity in clinical trials.
The European Commission has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of platinum-based chemotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have no sensitizing epidermal growth factor receptor mutation or anaplastic lymphoma kinase translocation.
In a phase III trial, Keytruda (pembrolizumab) plus Lenvima (lenvatinib) met the primary endpoint of progression-free survival as first-line treatment of advanced renal cell carcinoma.
In a phase IIb study, Tavo (tavokinogene telseplasmid) in combination with Keytruda (pembrolizumab) led to a 30% overall response rate in the first 54 out of 100 planned patients who have rigorously defined anti-PD1 checkpoint resistant metastatic melanoma.
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.
A study by researchers at the University of Pennsylvania found that early and repeated exposures to diagnostic imaging, such as X-rays and CT scans, may increase the risk of testicular cancer.
A study published published in JNCCN—Journal of the National Comprehensive Cancer Network analyzes the cost-effectiveness of olaparib, a PARP inhibitor, in the treatment of metastatic pancreatic cancer.
Researchers at the University of Virginia, in collaboration with Manchester, UK-based APIS Assay Technologies Ltd., have discovered Hormone-Upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase is detectable in non-invasive prostate cancer patient samples.
When they decided to launch a weekly breast cancer chat on Twitter, all breast cancer survivors and advocates Alicia Staley and Jody Schoger had was a hashtag and a dream.1
Abraham Chachoua was named director of the Lung Cancer Center at Perlmutter Cancer Center.
